{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:37:31Z","timestamp":1787801851787,"version":"build-2784847793"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T00:00:00Z","timestamp":1434412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T00:00:00Z","timestamp":1434412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1038\/tpj.2015.43","type":"journal-article","created":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T10:02:11Z","timestamp":1434448931000},"page":"280-285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":144,"title":["NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7042-009X","authenticated-orcid":false,"given":"Y","family":"Kakuta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kuroha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Negoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Kinouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Shimosegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,16]]},"reference":[{"key":"BFtpj201543_CR1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/gut.50.4.485","volume":"50","author":"AG Fraser","year":"2002","unstructured":"Fraser AG, Orchard TR, Jewell DP . The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485\u2013489.","journal-title":"Gut"},{"key":"BFtpj201543_CR2","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S0140-6736(71)90268-6","volume":"2","author":"JM Willoughby","year":"1971","unstructured":"Willoughby JM, Beckett J, Kumar PJ, Dawson AM . Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2: 944\u2013947.","journal-title":"Lancet"},{"key":"BFtpj201543_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(71)90598-8","volume":"2","author":"J Rhodes","year":"1971","unstructured":"Rhodes J, Bainton D, Beck P, Campbell H . Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2: 1273\u20131276.","journal-title":"Lancet"},{"key":"BFtpj201543_CR4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1136\/bmj.4.5945.627","volume":"4","author":"DP Jewell","year":"1974","unstructured":"Jewell DP, Truelove SC . Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974; 4: 627\u2013630.","journal-title":"Br Med J"},{"key":"BFtpj201543_CR5","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383\u20131395.","journal-title":"N Engl J Med"},{"key":"BFtpj201543_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/pds.926","volume":"13","author":"RB Gearry","year":"2004","unstructured":"Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA . Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2004; 13: 563\u2013567.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"BFtpj201543_CR7","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1097\/MIB.0b013e318281f28f","volume":"19","author":"M Chaparro","year":"2013","unstructured":"Chaparro M, Ordas I, Cabre E, Garcia-Sanchez V, Bastida G, Penalva M et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis 2013; 19: 1404\u20131410.","journal-title":"Inflamm Bowel Dis"},{"key":"BFtpj201543_CR8","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/ng.3093","volume":"46","author":"GA Heap","year":"2014","unstructured":"Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet 2014; 46: 1131\u20131134.","journal-title":"Nat Genet"},{"key":"BFtpj201543_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/FPC.0b013e3283449200","volume":"21","author":"J Bourgine","year":"2011","unstructured":"Bourgine J, Garat A, Allorge D, Crunelle-Thibaut A, Lo-Guidice JM, Colombel JF et al. Evidence for a functional genetic polymorphism of the Rho-GTPase Rac1. Implication in azathioprine response? Pharmacogenet Genomics 2011; 21: 313\u2013324.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj201543_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2174\/15748863113089990033","volume":"8","author":"Y Mazor","year":"2013","unstructured":"Mazor Y, Koifman E, Elkin H, Chowers Y, Krivoy N, Karban A et al. Risk factors for serious adverse effects of thiopurines in patients with Crohn's disease. Curr Drug Saf 2013; 8: 181\u2013185.","journal-title":"Curr Drug Saf"},{"key":"BFtpj201543_CR11","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0016-5085(00)70354-4","volume":"118","author":"JF Colombel","year":"2000","unstructured":"Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025\u20131030.","journal-title":"Gastroenterology"},{"key":"BFtpj201543_CR12","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/j.1440-1746.2009.05917.x","volume":"24","author":"N Takatsu","year":"2009","unstructured":"Takatsu N, Matsui T, Murakami Y, Ishihara H, Hisabe T, Nagahama T et al. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 2009; 24: 1258\u20131264.","journal-title":"J Gastroenterol Hepatol"},{"key":"BFtpj201543_CR13","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.2169\/internalmedicine.47.1268","volume":"47","author":"H Ban","year":"2008","unstructured":"Ban H, Andoh A, Tanaka A, Tsujikawa T, Sasaki M, Saito Y et al. Analysis of thiopurine S-methyltransferase genotypes in Japanese patients with inflammatory bowel disease. Intern Med 2008; 47: 1645\u20131648.","journal-title":"Intern Med"},{"key":"BFtpj201543_CR14","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/ng.3060","volume":"46","author":"SK Yang","year":"2014","unstructured":"Yang SK, Hong M, Baek J, Choi H, Zhao W, Jung Y et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 2014; 46: 1017\u20131020.","journal-title":"Nat Genet"},{"key":"BFtpj201543_CR15","first-page":"687","volume":"64","author":"SK Yang","year":"2014","unstructured":"Yang SK, Ye BD, Song K . ATG16L1 contributes to Crohn's disease susceptibility in Koreans: overmuch concern for ethnic difference? Gut 2014; 64: 687\u2013688.","journal-title":"Gut"},{"key":"BFtpj201543_CR16","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10038-007-0156-z","volume":"52","author":"K Yamazaki","year":"2007","unstructured":"Yamazaki K, Onouchi Y, Takazoe M, Kubo M, Nakamura Y, Hata A . Association analysis of genetic variants in IL23R, ATG16L1 and 5p13.1 loci with Crohn's disease in Japanese patients. J Hum Genet 2007; 52: 575\u2013583.","journal-title":"J Hum Genet"},{"key":"BFtpj201543_CR17","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/MIB.0b013e31828075e7","volume":"19","author":"A Hirano","year":"2013","unstructured":"Hirano A, Yamazaki K, Umeno J, Ashikawa K, Aoki M, Matsumoto T et al. Association study of 71 European Crohn's disease susceptibility loci in a Japanese population. Inflamm Bowel Dis 2013; 19: 526\u2013533.","journal-title":"Inflamm Bowel Dis"},{"key":"BFtpj201543_CR18","unstructured":"NCI N, DHHS. National Cancer Institute, Common Terminology Criteria for Adverse Events v4. NIH publication; # 09-7473 2009."},{"key":"BFtpj201543_CR19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s00535-003-1139-2","volume":"38","author":"T Hibi","year":"2003","unstructured":"Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T . Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol 2003; 38: 740\u2013746.","journal-title":"J Gastroenterol"},{"key":"BFtpj201543_CR20","doi-asserted-by":"publisher","first-page":"21541","DOI":"10.1074\/jbc.M112.363010","volume":"287","author":"Y Takagi","year":"2012","unstructured":"Takagi Y, Setoyama D, Ito R, Kamiya H, Yamagata Y, Sekiguchi M . Human MTH3 (NUDT18) protein hydrolyzes oxidized forms of guanosine and deoxyguanosine diphosphates: comparison with MTH1 and MTH2. J Biol Chem 2012; 287: 21541\u201321549.","journal-title":"J Biol Chem"},{"key":"BFtpj201543_CR21","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3109\/10428194.2013.825902","volume":"55","author":"Y Tanaka","year":"2014","unstructured":"Tanaka Y, Manabe A, Nakadate H, Kondoh K, Nakamura K, Koh K et al. Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients. Leuk Lymphoma 2014; 55: 1126\u20131131.","journal-title":"Leuk Lymphoma"},{"key":"BFtpj201543_CR22","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1093\/hmg\/dds302","volume":"21","author":"G Stocco","year":"2012","unstructured":"Stocco G, Yang W, Crews KR, Thierfelder WE, Decorti G, Londero M et al. PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet 2012; 21: 4793\u20134804.","journal-title":"Hum Mol Genet"},{"key":"BFtpj201543_CR23","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/ajg.2014.89","volume":"109","author":"RL Roberts","year":"2014","unstructured":"Roberts RL, Wallace MC, Seinen ML, Krishnaprasad K, Chew A, Lawrance I et al. PACSIN2 does not influence thiopurine-related toxicity in patients with inflammatory bowel disease. Am J Gastroenterol 2014; 109: 925\u2013927.","journal-title":"Am J Gastroenterol"},{"key":"BFtpj201543_CR24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1399-0039.1995.tb03127.x","volume":"46","author":"M Bunce","year":"1995","unstructured":"Bunce M, O'Neill CM, Barnardo MC, Krausa P, Browning MJ, Morris PJ et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995; 46: 355\u2013367.","journal-title":"Tissue Antigens"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201543.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201543","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201543.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T11:11:34Z","timestamp":1647947494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,16]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["BFtpj201543"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2015.43","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,16]]},"assertion":[{"value":"9 February 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}